Chronic lymphocytic leukemia
Testing for prognosis and risk stratification
Our chronic lymphocytic leukemia (CLL) testing provides important prognostic determination and assists physicians when determining the appropriate risk stratification to make informed treatment decisions for patients. Our offerings meet all National Comprehensive Cancer Network (NCCN) and CLL-International Prognostic Index (CLL-IPI) testing recommendations.
As highlighted by the new International Workshop on Chronic Lymphocytic Leukemia (IWCLL) recommendations and updated CLL-IPI, the need for all-encompassing testing for CLL patients is of utmost importance. Mayo Clinic Laboratories offers all testing recommended by the CLL-IWG, including a CLL FISH panel, molecular testing for IGHV and TP53 mutations, and an SLL FISH panel that is available on paraffin embedded tissue. Because all testing is performed at one facility, the need for splitting patient samples is reduced and continuity of care is increased.
Which test should I order?
Testing for diagnosis
Testing for monitoring
IGHV and TP53 Sequencing: Clinical Utility in Chronic Lymphocytic Leukemia (CLL)
Our goals today are, first of all, to understand the use of prognostic markers in CLL patients; second, to highlight the importance of molecular analyses for IGHV and TP53 sequencing in CLL patients; third, to understand how IGHV mutation analysis provides prognostic information in CLL and can help inform clinicians about possible treatment decisions; and finally, to recognize that TP53 mutations identified by sequencing studies are associated with poor outcomes, since those patients are more likely to be resistant to standard therapeutic regimens.
Learn more about how to order these evaluations at your institution.
Curtis Hanson, M.D., discusses prognostic markers for chronic lymphocytic leukemia
Curtis Hanson, M.D., discusses the importance of detecting immunoglobulin heavy-chain variable (IGHV) gene mutation when acquiring prognostic and potentially therapeutic information in chronic lymphocytic leukemia (CLL) patients in CAP TODAY.